Literature DB >> 17899018

Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers.

James P Zacny1, Stephanie A Lichtor.   

Abstract

RATIONALE: Nonmedical use and abuse of prescription opioids is a significant problem in the USA. Little attention has been paid to assessing the relative psychopharmacological profile (including abuse liability-related effects) of specific prescription opioids.
OBJECTIVES: The aim of this study is to directly compare the psychopharmacological profile of two oral opioids within the same subject.
METHODS: A randomized, placebo-controlled, crossover study was done in which 20 non-drug-abusing volunteers ingested 10 and 20 mg of oxycodone, 30 and 60 mg of morphine, and placebo in separate sessions. Drug doses were equated on an objective measure of opiate effects: miosis. Subjective, psychomotor, reinforcing, and physiological effects of the opioids were assessed.
RESULTS: In general, the two opioids at equimiotic doses produced similar prototypic opiate-like effects and psychomotor impairment of similar magnitude. However, several effects were found only with 20 mg oxycodone. Both drugs produced abuse liability-related subjective effects but also dysphoric effects, particularly with 60 mg morphine. Neither drug at either dose functioned as a reinforcer, as measured by the Multiple Choice Procedure. Relative potency ratios indicated an average oxycodone/morphine [corrected] ratio of 1:3 [corrected]
CONCLUSIONS: The psychopharmacological profile of oxycodone and morphine at equimiotic doses had many similarities; however, differences were found in producing abuse liability-related and dysphoric effects. In the medical community, it is commonly accepted that oral oxycodone is 1.5 to 2 times as potent as oral morphine in producing analgesia; using this ratio, although patients may experience similar degrees of pain relief, those receiving oxycodone may be experiencing stronger and potentially different psychopharmacological effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899018      PMCID: PMC2562738          DOI: 10.1007/s00213-007-0937-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  Use of miotic effect in evaluating analgesic drugs in man.

Authors:  H F FRASER; T L NASH; G D VANHORN; H ISBELL
Journal:  Arch Int Pharmacodyn Ther       Date:  1954-08-01

Review 2.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

3.  Human drug abuse liability assessment: opioids and analgesics.

Authors:  G E Bigelow
Journal:  Br J Addict       Date:  1991-12

4.  A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone.

Authors:  D P Benziger; J Miotto; R P Grandy; G B Thomas; R E Swanton; R D Fitzmartin
Journal:  J Pain Symptom Manage       Date:  1997-02       Impact factor: 3.612

5.  A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model.

Authors:  Camilla Staahl; Lona Louring Christrup; Søren Due Andersen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Pain       Date:  2006-04-04       Impact factor: 6.961

6.  Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.

Authors:  Kim K Lemberg; Vesa K Kontinen; Antti O Siiskonen; Kaarin M Viljakka; Jari T Yli-Kauhaluoma; Esa R Korpi; Eija A Kalso
Journal:  Anesthesiology       Date:  2006-10       Impact factor: 7.892

7.  Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users.

Authors:  James P Zacny; Sandra Gutierrez; Shahla A Bolbolan
Journal:  Drug Alcohol Depend       Date:  2005-01-12       Impact factor: 4.492

8.  Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP.

Authors:  Manuel Tancer; Chris-Ellyn Johanson
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

9.  Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain.

Authors:  E Bruera; M Belzile; E Pituskin; R Fainsinger; A Darke; Z Harsanyi; N Babul; I Ford
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

10.  Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys.

Authors:  Patrick M Beardsley; Mario D Aceto; Charles D Cook; Edward R Bowman; Jennifer L Newman; Louis S Harris
Journal:  Exp Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.157

View more
  36 in total

1.  Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers.

Authors:  Cynthia M Gooch; Brian C Rakitin; Ziva D Cooper; Sandra D Comer; Peter D Balsam
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

2.  Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-08-23       Impact factor: 3.533

3.  Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers.

Authors:  James P Zacny; Sandra Gutierrez
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

4.  Opioid modulation of resting-state anterior cingulate cortex functional connectivity.

Authors:  Stephanie M Gorka; Daniel A Fitzgerald; Harriet de Wit; Mike Angstadt; K Luan Phan
Journal:  J Psychopharmacol       Date:  2014-09-18       Impact factor: 4.153

Review 5.  Oxycodone combinations for pain relief.

Authors:  R B Raffa; J V Pergolizzi; D J Segarnick; R J Tallarida
Journal:  Drugs Today (Barc)       Date:  2010-06       Impact factor: 2.245

6.  The Contribution of Differential Opioid Responsiveness to Identification of Opioid Risk in Chronic Pain Patients.

Authors:  Stephen Bruehl; John W Burns; Steven D Passik; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; Erik Schuster; Daria Orlowska; Christopher R France
Journal:  J Pain       Date:  2015-04-16       Impact factor: 5.820

7.  Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.

Authors:  Sandra D Comer; Verena E Metz; Ziva D Cooper; William J Kowalczyk; Jermaine D Jones; Maria A Sullivan; Jeanne M Manubay; Suzanne K Vosburg; Mary E Smith; Deena Peyser; Phillip A Saccone
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

8.  Prescription Opioid Type and the Likelihood of Prolonged Opioid Use After Orthopaedic Surgery.

Authors:  Matthew Basilico; Abhiram R Bhashyam; Mitchel B Harris; Marilyn Heng
Journal:  J Am Acad Orthop Surg       Date:  2019-05-01       Impact factor: 3.020

9.  Psychopharmacological effects of oxycodone in healthy volunteers: roles of alcohol-drinking status and sex.

Authors:  James P Zacny; Melinda Drum
Journal:  Drug Alcohol Depend       Date:  2009-11-30       Impact factor: 4.492

10.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.